Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Judy Ellen Garber, M.D.

Co-Author

This page shows the publications co-authored by Judy Garber and Huma Rana.
Connection Strength

3.727
  1. Genotype-phenotype associations among panel-based TP53+ subjects. Genet Med. 2019 11; 21(11):2478-2484.
    View in: PubMed
    Score: 0.816
  2. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing. J Natl Cancer Inst. 2018 08 01; 110(8):863-870.
    View in: PubMed
    Score: 0.772
  3. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics. Cancer. 2022 03 15; 128(6):1275-1283.
    View in: PubMed
    Score: 0.243
  4. Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precis Oncol. 2021 11; 5:1677-1686.
    View in: PubMed
    Score: 0.242
  5. Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. Eur J Med Genet. 2021 Dec; 64(12):104359.
    View in: PubMed
    Score: 0.241
  6. Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. Am J Case Rep. 2020 Dec 27; 21:e927415.
    View in: PubMed
    Score: 0.228
  7. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol. 2021 02; 160(2):457-463.
    View in: PubMed
    Score: 0.227
  8. Prevalence of germline variants in inflammatory breast cancer. Cancer. 2019 07 01; 125(13):2194-2202.
    View in: PubMed
    Score: 0.202
  9. A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings. J Community Genet. 2018 Jul; 9(3):233-241.
    View in: PubMed
    Score: 0.184
  10. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 2014 Jun; 35(6):654-62.
    View in: PubMed
    Score: 0.145
  11. Vulvar Melanoma in association with germline MITF p.E318K variant. Cancer Genet. 2022 Apr; 262-263:102-106.
    View in: PubMed
    Score: 0.062
  12. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021 Dec; 39:107653.
    View in: PubMed
    Score: 0.061
  13. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 09 09; 138(10):898-911.
    View in: PubMed
    Score: 0.060
  14. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.058
  15. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med. 2020 04; 22(4):709-718.
    View in: PubMed
    Score: 0.053
  16. Trans-counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants. J Genet Couns. 2019 06; 28(3):708-716.
    View in: PubMed
    Score: 0.050
  17. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genet Med. 2017 07; 19(7):787-795.
    View in: PubMed
    Score: 0.043
  18. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016 02; 14(2):153-62.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.